Topics
All Topics

The Lower Costs, More Transparency Act (H.R. 5378) currently before Congress aims to increase price transparency in health care and address the high cost of prescription drugs. One of the provisions of the bill would change the way Medicare pays for physician administered drugs. Currently, Medicare pays a higher price for drugs that are administered in a hospital outpatient setting than drugs that...

 HCCI's research with iFHP on international comparisons of health care prices was cited in an article in The New York Times on COVID-19 test prices.  From the article:  "How can a simple coronavirus test cost $100 in one lab and 2,200 percent more in another? It comes back to a fundamental fact about the American health care system: The government does not regulate health care price...

HCCI's work with iFHP on international comparisons of health care prices was featured in a New York Times article.   In the U.S., an Angioplasty Costs $32,000. Elsewhere? Maybe $6,400. - The New York Times Enter some description here... https://www.nytimes.com/2019/12/27/upshot/expensive-health-care-world-comparison.html?smid=nytcore-ios-share

HCCI's work with iFHP on international comparisons of health care price was featured in a Vox article.   America’s health care costs problem, explained in 4 charts - Vox America’s health care prices problem, in four charts. https://www.vox.com/policy-and-politics/2019/12/17/21024614/us-health-care-costs-medical-prices

The International Federation of Health Plans (iFHP), a CEO network of the global health insurance industry based in London, in partnership with the Health Care Cost Institute (HCCI) in the United States, and iFHP member companies in eight countries, today published the latest International Comparison of Health Prices Report. The report compares the median prices paid by a sample of private he...

HCCI recently provided cost information  for iron infusions for an NPR article. From the article: "An analysis of private insurance claims conducted by the Health Care Cost Institute, an independent research group funded by insurers, found that in 2017, private health plans paid $4,316 per visit, on average, if a patient received Injectafer infusions. Feraheme, the next most expensive in...